Drug Profile


Alternative Names: GYKI-53773; LY-300164

Latest Information Update: 29 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IVAX Drug Research Institute
  • Developer Teva Pharmaceutical Industries
  • Class Antiepileptic drugs; Antineoplastics; Neuroprotectants; Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Dyskinesias; Epilepsy; Glioblastoma; Multiple sclerosis

Most Recent Events

  • 23 Jun 2010 Discontinued - Phase-II for Glioblastoma in USA (PO)
  • 08 Jun 2010 Teva Pharmaceutical Industries terminates phase II trial [NCT00982150] in Amyotrophic Lateral Sclerosis in the USA, Canada, EU and Israel
  • 18 May 2010 Interim efficacy and adverse event data from a phase II trial in Amyotrophic lateral sclerosis released by Teva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top